{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:03:09Z","timestamp":1776106989083,"version":"3.50.1"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Even in a lupus low disease activity state (LLDAS), many patients with SLE continue to face residual symptoms and disease burden. We aimed to evaluate the quality of life, activity impairment and overall work productivity impairment among patients in LLDAS. Residual disease burden was also evaluated for patients in LLDAS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, cross-sectional study enrolled Japanese outpatients with SLE. Patients completed patient-reported outcome (PRO) questionnaires, including LupusPRO, Work Productivity and Activity Impairment-Lupus, EQ-5D-5L and Health Assessment Questionnaire-Disability Index. Disease activity and organ damage were investigator-assessed. The primary objective was to assess the residual burden in patients in LLDAS and to investigate the association of LupusPRO domains with activity impairment using multivariate regression analysis. Other objectives were to investigate the relationship between overall work productivity impairment or activity impairment and other PRO or disease activity measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analysis set included 205 patients; 93.2% were female, mean (SD) age at index date was 52.5 (14.7) years, mean (SD) duration of morbidity was 167.2 (125.2) months and 164 were in LLDAS. The mean per cent overall work productivity impairment was 22.8% and mean per cent activity impairment was 30.0% for the LLDAS group. Among patients in LLDAS, overall work productivity impairment was significantly associated with the LupusPRO domains Desires-Goals, Body Image and Pain Vitality, and activity impairment was significantly associated with the LupusPRO domains Pain Vitality, Physical Health and Lupus Symptoms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with SLE in LLDAS still experience symptoms associated with activity impairment. Work productivity also showed impairments. Improving their quality of life and achieving social remission will require ongoing monitoring of PROs and tailoring treatments to optimise these outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>jRCT1030210647.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2024-001291","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T03:55:11Z","timestamp":1737345311000},"page":"e001291","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"},{"name":"Rheumatism and Diabetes, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2474-9943","authenticated-orcid":false,"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhide","family":"Kusaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"},{"name":"Department of Rheumatology, Yamaguchi-ken Saiseikai Shimonoseki General Hospital, Shimonoseki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunpei","family":"Kosaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"},{"name":"Department of Clinical Immunology, Kitakyushu General Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Nakatsuka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japan Community Health Care Organization Fukuoka Yutaka Central Hospital, Nogata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Saito","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"},{"name":"Department of Clinical Immunology and Rheumatology, Tobata General Hospital, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Wakayama Medical University Hospital, Wakayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7941-8396","authenticated-orcid":false,"given":"Yoshiyuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-0590","authenticated-orcid":false,"given":"Toshiki","family":"Yabe-Wada","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Data Science, Evidence & Observational Research, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Arita","sequence":"additional","affiliation":[{"name":"Data Science, Evidence & Observational Research, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Medical Evidence Biopharma, Evidence & Observational Research, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Immunology, Respiratory & Immunology, Medical Department, AstraZeneca K.K, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University Hospital, Sagamihara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"2025091511294140000_12.1.e001291.1","doi-asserted-by":"crossref","first-page":"v29","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025091511294140000_12.1.e001291.2","first-page":"1577","article-title":"SLE mortality remains disproportionately high, despite improvements over the last decade","volume":"27","author":"Singh","year":"2018","journal-title":"Lupus (Los Angel)"},{"key":"2025091511294140000_12.1.e001291.3","doi-asserted-by":"crossref","first-page":"101814","DOI":"10.1016\/j.berh.2022.101814","article-title":"Systemic lupus erythematosus","volume":"36","author":"Tanaka","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025091511294140000_12.1.e001291.4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025091511294140000_12.1.e001291.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2025091511294140000_12.1.e001291.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091511294140000_12.1.e001291.7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13075-018-1647-3","article-title":"Effect of subcutaneous tocilizumab treatment on work\/housework status in biologic-na\u00efve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study","volume":"20","author":"Tanaka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025091511294140000_12.1.e001291.8","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2025091511294140000_12.1.e001291.9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40744-021-00328-6","article-title":"Patient experiences, satisfaction, and expectations with current systemic lupus erythematosus treatment: Results of the SLE-UPDATE survey","volume":"8","author":"Birt","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025091511294140000_12.1.e001291.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket300"},{"key":"2025091511294140000_12.1.e001291.11","doi-asserted-by":"crossref","DOI":"10.4081\/hpr.2013.932","article-title":"Quality of life in chronic disease patients","volume":"1","author":"Megari","year":"2013","journal-title":"Health Psychol Res"},{"key":"2025091511294140000_12.1.e001291.12","unstructured":"European Medicines Agency . Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005."},{"key":"2025091511294140000_12.1.e001291.13","unstructured":"Food and Drug Administration . Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009."},{"key":"2025091511294140000_12.1.e001291.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-014-0116-1","article-title":"Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance","volume":"12","author":"Holloway","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2025091511294140000_12.1.e001291.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081022"},{"key":"2025091511294140000_12.1.e001291.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.12.005"},{"key":"2025091511294140000_12.1.e001291.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0110-5"},{"key":"2025091511294140000_12.1.e001291.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket171"},{"key":"2025091511294140000_12.1.e001291.19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130046"},{"key":"2025091511294140000_12.1.e001291.20","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2012.677857"},{"key":"2025091511294140000_12.1.e001291.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-017-0200-5","article-title":"Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)","volume":"18","author":"Chaigne","year":"2017","journal-title":"BMC Immunol"},{"key":"2025091511294140000_12.1.e001291.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1256-6","article-title":"Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study","volume":"19","author":"Golder","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025091511294140000_12.1.e001291.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2095-4","article-title":"Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study","volume":"22","author":"Louthrenoo","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025091511294140000_12.1.e001291.24","doi-asserted-by":"crossref","first-page":"v63","DOI":"10.1093\/rheumatology\/keaa427","article-title":"The patient\u2019s perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?","volume":"59","author":"Kernder","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025091511294140000_12.1.e001291.25","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkab029","article-title":"Impaired hand function and performance in activities of daily living in systemic lupus erythematosus, even in patients achieving lupus low disease activity state (LLDAS)","volume":"5","author":"Keramiotou","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2025091511294140000_12.1.e001291.26","first-page":"849","article-title":"The Japanese LupusPRO: A cross-cultural validation of an outcome measure for lupus","volume":"26","author":"Inoue","year":"2017","journal-title":"Lupus (Los Angel)"},{"key":"2025091511294140000_12.1.e001291.27","unstructured":"EuroQol Research Foundation . EQ-5D-5L about. 2019. Available: https:\/\/euroqol.org\/eq-5dinstruments\/eq-5d-5l-about\/ [Accessed 29 Sep 2023]."},{"key":"2025091511294140000_12.1.e001291.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.11465"},{"key":"2025091511294140000_12.1.e001291.29","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2025091511294140000_12.1.e001291.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2025091511294140000_12.1.e001291.31","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025091511294140000_12.1.e001291.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2025091511294140000_12.1.e001291.33","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v036.i11"},{"key":"2025091511294140000_12.1.e001291.34","first-page":"1577","article-title":"Correlation between irreversible organ damage and the quality of life of patients with systemic lupus erythematosus: The Kyoto Lupus Cohort survey","volume":"30","author":"Takase","year":"2021","journal-title":"Lupus (Los Angel)"},{"key":"2025091511294140000_12.1.e001291.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew377"},{"key":"2025091511294140000_12.1.e001291.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s41649-021-00191-1","article-title":"Relational autonomy, the right to reject treatment, and advance directives in Japan","volume":"14","author":"Asagumo","year":"2022","journal-title":"Asian Bioeth Rev"},{"key":"2025091511294140000_12.1.e001291.37","doi-asserted-by":"crossref","unstructured":"Fanouriakis A , Kostopoulou M , Andersen J , et al . EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2023. doi:10.1136\/ard-2024-226636","DOI":"10.1136\/ard-2024-225617"},{"key":"2025091511294140000_12.1.e001291.38","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10050998","article-title":"High comorbidity burden in patients with SLE: Data from the Community-Based Lupus Registry of Crete","volume":"10","author":"Gergianaki","year":"2021","journal-title":"J Clin Med"},{"key":"2025091511294140000_12.1.e001291.39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac613"},{"key":"2025091511294140000_12.1.e001291.40","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001202","article-title":"Impact of disease activity patterns on health-related quality of life (HRQoL) in patients with systemic lupus erythematosus (SLE)","volume":"11","author":"Elefante","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2025091511294140000_12.1.e001291.41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/acr.22922","article-title":"Influence of education on disease activity and damage in systemic lupus erythematosus: Data from the 1000 Canadian Faces of Lupus","volume":"69","author":"George","year":"2017","journal-title":"Arthritis Care & Research"},{"key":"2025091511294140000_12.1.e001291.42","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000542","article-title":"Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025091511294140000_12.1.e001291.43","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/rheumatology\/kead407","article-title":"Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus","volume":"63","author":"Thibault","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025091511294140000_12.1.e001291.44","doi-asserted-by":"crossref","unstructured":"Parodis I , Haugli-Stephens T , Dominicus A , et al . Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up. Rheumatology (Oxford) 2024. doi:10.1093\/rheumatology\/keae120","DOI":"10.1136\/lupus-2024-el.30"},{"key":"2025091511294140000_12.1.e001291.45","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac185"},{"key":"2025091511294140000_12.1.e001291.46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1044207320933211","article-title":"Absenteeism and presenteeism among American workers","volume":"32","author":"Maestas","year":"2021","journal-title":"J Disabil Policy Stud"},{"key":"2025091511294140000_12.1.e001291.47","first-page":"33","article-title":"Multicenter study to assess presenteeism in systemic lupus erythematosus and its relationship with clinical and sociodemographic features","volume":"27","author":"Cosatti","year":"2018","journal-title":"Lupus (Los Angel)"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2024-001291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:29:51Z","timestamp":1757960991000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2024-001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,19]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/lupus-2024-001291"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2024-001291","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}